Amal Therapeutics SA, based in Geneva, Switzerland, is a pioneering company in the field of cancer immunotherapy. The company focuses on developing therapeutic vaccines that stimulate the immune system in a unique way to combat cancer. Amal Therapeutics' proprietary protein-based immunisation platform is self-adjuvanting, meaning it enhances the body's immune response without needing additional substances, and can deliver multiple antigens in a single vaccine. This technology aims to overcome the challenges of effective anti-cancer therapy by providing a robust and targeted immune response against cancer cells.

The company's most advanced product, ATP128, is a therapeutic vaccine designed for the treatment of metastatic colorectal cancer. Amal Therapeutics operates in the biopharmaceutical market, primarily serving patients with cancer and collaborating with major pharmaceutical companies. For instance, they have entered a clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091, a move that underscores their commitment to advancing cancer treatment.

Amal Therapeutics' business model revolves around research and development, clinical trials, and strategic partnerships. Revenue is generated through collaborations, licensing agreements, and potentially from the commercialization of their therapeutic vaccines. The acquisition by Boehringer Ingelheim has significantly enriched their cancer immunology portfolio, providing additional resources and expertise to accelerate the development of novel cancer vaccines.

Keywords: cancer immunotherapy, therapeutic vaccines, protein-based immunisation, metastatic colorectal cancer, ATP128, self-adjuvanting platform, biopharmaceutical, clinical collaboration, Boehringer Ingelheim, cancer treatment.